THERAPY OF TP53 MUT MDS

被引：0
|
作者：
Sallman, D. [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IS24
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Role of TP53 mutational status in MDS and AML with complex chromosomal abnormalities
    Schaab, R.
    Ganster, C.
    Rietkoetter, E.
    Dierks, S.
    Shirneshan, K.
    Haase, D.
    Oncology Research and Treatment, 2015, 38 : 185 - 185
  • [32] Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
    Sallman, David A.
    Al Ali, Najla
    Yun, Seongseok
    Padron, Eric
    Song, Jinming
    Hussaini, Mohammad Omar
    Talati, Chetasi
    Sweet, Kendra L.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2018, 132
  • [33] TP53 mutations in MCL: more therapy is not better
    Cohen, Jonathon B.
    BLOOD, 2017, 130 (17) : 1876 - 1877
  • [34] TP53 and therapy-related myeloid neoplasms
    Chung, Jae
    Sallman, David A.
    Padron, Eric
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 98 - 103
  • [35] Should mutant TP53 be targeted for cancer therapy?
    Zilu Wang
    Andreas Strasser
    Gemma L. Kelly
    Cell Death & Differentiation, 2022, 29 : 911 - 920
  • [36] Should mutant TP53 be targeted for cancer therapy?
    Wang, Zilu
    Strasser, Andreas
    Kelly, Gemma L.
    CELL DEATH AND DIFFERENTIATION, 2022, 29 (05): : 911 - 920
  • [37] Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
    Tesio, Melania
    HEMASPHERE, 2023, 7 (02):
  • [38] TP53 Action and the Consequences of TP53 Mutation in Acute Myeloid Leukemia
    Lowe, Scott W.
    BLOOD, 2019, 134
  • [39] Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway
    Saba, Karim H.
    Difilippo, Valeria
    Kovac, Michal
    Cornmark, Louise
    Magnusson, Linda
    Nilsson, Jenny
    van den Bos, Hilda
    Spierings, Diana C. J.
    Bidgoli, Mahtab
    Jonson, Tord
    Sumathi, Vaiyapuri P.
    Brosjoe, Otte
    Staaf, Johan
    Foijer, Floris
    Styring, Emelie
    Nathrath, Michaela
    Baumhoer, Daniel
    Nord, Karolin H.
    JOURNAL OF PATHOLOGY, 2024, 262 (02): : 147 - 160
  • [40] TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53
    Takahashi, Koichi
    Kantarjian, Hagop M.
    Patel, Keyur
    Bueso-Ramos, Carlos E.
    Kadia, Tapan
    Jabbour, Elias
    DiNardo, Courtney
    Daver, Naval
    Pierce, Sherry
    Futreal, Andrew
    Garcia-Manero, Guillermo
    BLOOD, 2015, 126 (23)
12345